Key U.S. Senator Sinema agrees to $430 billion drug, energy bill

Published 08/04/2022, 03:22 PM
Updated 08/04/2022, 11:01 PM
© Reuters. FILE PHOTO: U.S. Senate Majority Leader Chuck Schumer (D-NY) at the U.S. Capitol in Washington, U.S. August 2, 2022.  REUTERS/Jonathan Ernst/File Photo

By Scott Malone

WASHINGTON (Reuters) -Democratic U.S. Senator Kyrsten Sinema said on Thursday she agreed to "move forward" on a $430 billion drug pricing, energy and tax bill, subject to a Senate arbiter's approval of the bill, which Democrats intend to pass over Republican objections.

Senate Majority Leader Chuck Schumer said earlier on Thursday the chamber would convene on Saturday to vote on a motion to proceed and then begin debate on the bill.

The bill known as the Inflation Reduction Act, introduced last week by Schumer and Democratic Senator Joe Manchin, is a key priority for Democrats and President Joe Biden ahead of November's election battle for control of the U.S. Congress.

The act will help people save money on prescription drugs and health premiums, Biden said in a statement on Thursday.

"It will make our tax system more fair by making corporations pay a minimum tax," he said.

With the 100-seat Senate split 50-50, Democrats plan to pass the bill without Republican support through a parliamentary process known as reconciliation.

But they cannot afford to lose support from a single lawmaker. Sinema's agreement was a critical breakthrough. Another worry is COVID-19 - senators can only vote in person, so Schumer will need his full caucus to be present and healthy to pass the measure if Republicans remain unified in opposition.

Sinema said she had reached an agreement with other Democrats to remove a provision that would impose new taxes on carried interest. Without the provision, private equity and hedge fund financiers can continue to pay the lower capital gains tax rate on much of their income, instead of the higher income tax rate paid by wage-earners.

She cautioned that her agreement to "move forward" was subject to the review of the Senate parliamentarian. The parliamentarian has to approve the contents of the bill to allow it to move forward through the "reconciliation" process that Democrats plan to use to bypass the chamber's normal rules requiring 60 Senators to agree to advance most legislation.

© Reuters. FILE PHOTO: Senator Kyrsten Sinema, a Democrat from Arizona, speaks during a Senate Homeland Security and Governmental Affairs Committee confirmation hearing for Shalanda Young, director of the Office of Management and Budget (OMB) nominee for U.S. President Joe Biden, in Washington, D.C., U.S., February 1, 2022. Bonnie Cash/Pool via REUTERS

Schumer, in a statement, said, he believed he now had the votes to pass the bill.

"The agreement preserves the major components of the Inflation Reduction Act, including reducing prescription drug costs, fighting climate change, closing tax loopholes exploited by big corporations and the wealthy, and reducing the deficit by $300 billion," Schumer said.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2025 - Fusion Media Limited. All Rights Reserved.